499 results on '"Sportoletti, Paolo"'
Search Results
2. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
3. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
4. Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia
5. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
6. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
7. Genetic variation in NOTCH1 is associated with overweight and obesity in Brazilian elderly.
8. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
9. GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL
10. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
11. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
12. Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy
13. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort
14. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
15. NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models
16. Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice
17. Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia
18. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
19. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia
20. Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study
21. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
22. Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita
23. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
24. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
25. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study
26. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
27. NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential
28. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling
29. P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
30. P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
31. P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
32. P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
33. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
34. PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
35. Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia
36. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
37. GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
38. Clinical-Grade–Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell–Dependent Graft-versus-Leukemia Effect in Murine Models
39. Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study
40. Therapeutic targeting of chronic lymphocytic leukemia by silver nanoparticles
41. Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
42. Data from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
43. Supplementary Tables from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
44. Supplementary Figures from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
45. Supplementary Appendix from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
46. Supplementary Figure Legends from A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells
47. Supplementary Figures S1 - S5 from A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells
48. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
49. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
50. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.